Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346705 | 0.98 | KEAP1 (0.52) | NCF1KEAP1KCNQ2MAPK1NPC1 | |
| Hydrochloric Acid SCHEMBL10710768 | 0.98 | NCF1 (0.47) | NCF1KEAP1KCNQ2MAPK1NPC1 | |
| SCHEMBL4960474 | 0.91 | KDM4E (0.52) | NCF1KDM4EALDH1A1PLA2G1BRAB9A | |
| SCHEMBL12416584 | 0.82 | KDM4E (0.45) | NCF1KDM4EALDH1A1PLA2G1BRAB9A | |
| SCHEMBL12368809 | 0.82 | NCF1 (0.61) | NCF1MAPK1KDM4EALDH1A1PLA2G1B | |
| SCHEMBL2384862 | 0.82 | ADRB1 (0.61) | NCF1KDM4EALDH1A1HTR7 | |
| SCHEMBL1715455 | 0.82 | AKR1C3 (0.50) | NCF1NPC1KDM4EALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL10711290 | 0.81 | NCF1 (0.59) | NCF1MAPK1KDM4EALDH1A1PLA2G1B | |
| SCHEMBL18756980 | 0.81 | KMT2A (0.43) | NCF1KEAP1KCNQ2MAPK1NPC1 | |
| Ammonia Solution, Strong SCHEMBL7888875 | 0.81 | KEAP1 (0.47) | NCF1KEAP1KCNQ2MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0010460-B1 | PYRROLIDINE-2-METHANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | PHARMUKA LABORATOIRES (FR) | 1982-01-27 | — | — | EP | claimed |
| EP-0010460-A1 | Pyrrolidine-2-methanol derivatives, process for their preparation and medicaments containing them | PHARMUKA LABORATOIRES (FR) | 1980-04-30 | — | — | EP | claimed |
| US-12180189-B2 | Proteostasis regulators | Kineta, Inc. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240116894-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2024-04-11 | — | — | US | disclosed |
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3814336-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | Kineta, Inc. | 2020-09-24 | — | — | US | disclosed |
| EP-3552664-A1 | PROTEOSTASIS REGULATORS | Proteostasis Therapeutics, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2707101-B1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS INC (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-103635230-B | Albumen homeostasis conditioning agent | 普罗蒂斯特斯治疗公司 | 2017-10-31 | — | — | CN | disclosed |
| US-9556166-B2 | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2707101-A1 | PROTEOSTASIS REGULATORS | Proteostasis Therapeutics, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| CN-103635230-A | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS INC | 2014-03-12 | — | — | CN | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | NCF1 3703/4885KEAP1 168/4885KCNQ2 3571/4885 |
| US-11746098-B2 | Proteasome activity enhancing compounds | PSMG3, PSMC1, PSMB11 | NCF1 2696/4885KEAP1 152/4885KCNQ2 4320/4885 |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | NCF1 2696/4885KEAP1 152/4885KCNQ2 4320/4885 |
| US-20240116894-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | NCF1 2696/4885KEAP1 152/4885KCNQ2 4320/4885 |
| US-12180189-B2 | Proteostasis regulators | PSMG3, VCP, HSPA5 | NCF1 3703/4885KEAP1 168/4885KCNQ2 3571/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | NCF1 293/4885KEAP1 331/4885KCNQ2 2659/4885 |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | NCF1 3703/4885KEAP1 168/4885KCNQ2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.